Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prolong recurrence-free survival or survival compared with a regimen that contained only standard agents. Patients with triple-negative breast cancer had favorable survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgroup analysis.

 JAMA Oncol